Department of Spine Surgery, Third Xiangya Hospital, Central South University, Changsha, China.
Department of Hepatopancreatobiliary Surgery, The Third Xiangya Hospital, Central South University, Changsha, China.
Front Immunol. 2022 Oct 6;13:967076. doi: 10.3389/fimmu.2022.967076. eCollection 2022.
BACKGROUND: Immunotherapy has shown great potential for the treatment of multiple cancer and has been proven to be closely related to the tumor microenvironment. This article reveals collaborations and interactions among authors, nations, organizations, and periodicals assesses the knowledge base, and discovers hot tendencies and new topics associated with immunotherapy-tumor microenvironment (TME) research. METHODS: This article utilized bibliometrics and visual methods to provide a comprehensive overview of immunotherapy-TME research. Our team retrieved the WoSCC for research and reviews associated with immunotherapy and the tumor microenvironment. VOSviewer and Citespace were primarily used for literature measurement and knowledge graph analysis. RESULT: All English articles and reviews on cancer immunotherapy effectiveness were collected, and 1,419 academic journals with 53,773 authors from 7,008 institutions in 92 countries/regions were found. Publications associated with immunotherapy-TME research were stably increasing. ( = 722) published the most papers on immunotherapy-TME, and ( = 6761) was the top co-cited journal. The published journals and co-cited journals focused on cancer and immunology fields. The League of European Research Universities ( = 978), Harvard University ( = 528), and the University of Texas system ( = 520) were the most productive institutions. Yang Liu ( 34) and Topalian ( 1978) ranked first among the top 10 scholars and co-cited scholars. Simultaneously, immunotherapy-TME researchers were involved in active collaborations. Elements of TME, the foundation of immunotherapy, and the application of immunotherapy in cancers represented the three principal aspects of immunotherapy-TME research. The latest hot spots are drug resistance, prognosis prediction, efficacy prediction, and mA. Nanomedicine and mA may be future hot topics. Future research in immunotherapy-TME may be directed at discovering how mA modification affects tumor development by altering the tumor microenvironment and exploring how to enhance response or reduce drug resistance to immunotherapy by reversing or mediating the physicochemical properties of the TME. CONCLUSIONS: MA and nanomedicine are also emerging hotspots in time zone diagrams with high centrality, and prognosis prediction using bioinformatics based on the development of prediction technology may be another future research hotspot.
背景:免疫疗法在治疗多种癌症方面显示出巨大潜力,并且已被证明与肿瘤微环境密切相关。本文揭示了作者、国家、组织和期刊之间的合作与互动,评估了知识基础,并发现了与免疫疗法-肿瘤微环境(TME)研究相关的热点趋势和新课题。
方法:本文利用文献计量学和可视化方法全面概述了免疫疗法-TME 研究。我们的团队检索了 WOSCC 中与癌症免疫疗法疗效相关的研究和综述。VOSviewer 和 Citespace 主要用于文献计量和知识图谱分析。
结果:共收集了所有关于癌症免疫疗法疗效的英文文章和综述,发现来自 92 个国家/地区的 7008 个机构的 53773 名作者发表了 1419 种与免疫疗法-TME 相关的学术期刊。与免疫疗法-TME 研究相关的出版物数量稳步增加。( = 722)发表的免疫疗法-TME 相关论文最多,( = 6761)是被引频次最高的期刊。发表的期刊和被引频次最高的期刊主要集中在癌症和免疫学领域。欧洲研究型大学联盟( = 978)、哈佛大学( = 528)和德克萨斯大学系统( = 520)是最具生产力的机构。( = 34)和 Topalian( = 1978)在排名前 10 的学者和高被引学者中排名第一。同时,免疫疗法-TME 研究人员之间也进行了积极的合作。TME 的元素、免疫疗法的基础以及免疫疗法在癌症中的应用是免疫疗法-TME 研究的三个主要方面。最新的热点是耐药性、预后预测、疗效预测和 mA。纳米医学和 mA 可能是未来的热点话题。免疫疗法-TME 的未来研究可能旨在发现 mA 修饰如何通过改变肿瘤微环境来影响肿瘤的发展,并探索如何通过逆转或调节 TME 的物理化学性质来增强对免疫疗法的反应或降低耐药性。
结论:mA 和纳米医学也是时区图中的新兴热点,具有较高的中心性,基于预测技术发展的生物信息学预后预测可能是另一个未来的研究热点。
Cancer Rep (Hoboken). 2024-8
Front Immunol. 2022
Front Immunol. 2023
Cancers (Basel). 2025-2-27
Cancer Rep (Hoboken). 2024-8
Medicine (Baltimore). 2024-6-14
Hum Vaccin Immunother. 2023-8
Aging (Albany NY). 2023-7-24
Front Physiol. 2022-4-7
Front Med (Lausanne). 2022-2-10
Adv Sci (Weinh). 2022-1